Schonfeld Strategic Advisors LLC Invests $2.79 Million in MacroGenics, Inc. (NASDAQ:MGNX)

Schonfeld Strategic Advisors LLC purchased a new stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 857,505 shares of the biopharmaceutical company's stock, valued at approximately $2,787,000. Schonfeld Strategic Advisors LLC owned about 1.37% of MacroGenics at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. American Century Companies Inc. purchased a new position in shares of MacroGenics during the fourth quarter valued at $38,000. Sanders Morris Harris LLC purchased a new position in MacroGenics in the fourth quarter valued at $40,000. Jump Financial LLC acquired a new stake in MacroGenics in the 4th quarter valued at $44,000. XML Financial LLC raised its holdings in shares of MacroGenics by 31.6% during the fourth quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company's stock valued at $75,000 after acquiring an additional 5,569 shares during the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in MacroGenics during the 4th quarter valued at about $89,000. 96.89% of the stock is currently owned by institutional investors.

MacroGenics Stock Up 3.0 %

MGNX stock traded up $0.05 during midday trading on Thursday, reaching $1.54. 299,044 shares of the company's stock traded hands, compared to its average volume of 1,124,962. MacroGenics, Inc. has a 1-year low of $0.99 and a 1-year high of $14.91. The company has a market cap of $96.84 million, a price-to-earnings ratio of -0.97 and a beta of 2.20. The company has a 50-day simple moving average of $1.66 and a two-hundred day simple moving average of $2.71.

MacroGenics (NASDAQ:MGNX - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The firm had revenue of $49.40 million for the quarter, compared to the consensus estimate of $34.17 million. Equities research analysts forecast that MacroGenics, Inc. will post -1.06 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on MGNX shares. HC Wainwright decreased their price target on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, March 25th. StockNews.com cut MacroGenics from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. Nine analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, MacroGenics currently has an average rating of "Hold" and an average target price of $7.38.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.